1-7 of 7
Peter Tan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

GB261, an Fc-Function Enabled and CD3 Affinity De-Tuned CD20/CD3 Bispecific Antibody, Demonstrated a Highly Advantageous Safety/Efficacy Balance in an Ongoing First-in-Human Dose-Escalation Study in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Yuqin Song, Zengjun Li, Ling Li, Zhengzi Qian, Keshu Zhou, Lei Fan, Peter Tan, Pratyush Giri, Zhiming Li, Melita Kenealy, Jie Jin, Wei Liu, Shafqat Inam, Yan Xie, Xia Guo, Wenduo He, Raymond Xu, Tong Li, Jun Zhu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1719.
https://doi.org/10.1182/blood-2023-188444
Published: 2023
Journal Articles

Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Dickran Kazandjian, Hang Quach, Hanlon Sia, Phoebe Joy Ho, Andrew Spencer, Mark A. Schroeder, Binod Dhakal, Tara Cochrane, Jeffrey A. Zonder, Nancy Yi, Dominique Duchesne, Tejas Shah, Andrew Garton, Vinu Menon, Sunitha Gn, Stefano Sammicheli, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Peter Tan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4707.
https://doi.org/10.1182/blood-2023-186241
Published: 2023
Journal Articles

PXS5505-MF-101: A Phase 1/2a Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Pankit Vachhani, Jana Baskar, Brett Charlton, Stanley Cheung, Wolfgang Jarolimek, Sung-Eun Lee, Peter Tan, Anne Marie Watson, Shang-Ju Wu
Journal: Blood
Blood (2023) 142 (Supplement 1): 625.
https://doi.org/10.1182/blood-2023-181383
Published: 2023
Journal Articles

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations

Elias Jabbour, Emma Searle, Maher Abdul-Hay, Sameem Abedin, Ibrahim Aldoss, Ana Alfonso Piérola, Juan Manuel Alonso-Dominguez, Patrice Chevallier, Carrye Cost, Nikki Daskalakis, Richard Dillon, Neil Dunavin, Jordi Esteve, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Sylvain Garciaz, Christina Guttke, Emmanuel Gyan, Brett Hiebert, Min Chul Kwon, Jonathan Miller, Teng Fong Ng, Kathryn Packman, Ulrike Philippar, Arnaud Pigneux, Christian Recher, Olga Salamero, Madhu Sanga, Richard M Stone, Peter Tan, Jan Willem Thuring, Trevor Tucker, Paresh Vyas
Journal: Blood
Blood (2023) 142 (Supplement 1): 57.
https://doi.org/10.1182/blood-2023-172422
Published: 2023
Journal Articles

EP0042, a Dual FLT3 and Aurora Kinase Inhibitor: Results from an Ongoing Phase I/IIa Dose-Finding/Dose Optimization Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia

David Taussig, David C. de Leeuw, Mojca Jongen-Lavrencic, Jenny O'Nions, Thinzar Koko, Emma Searle, Hendrik-Tobias Arkenau, Sue Brook, Charlotte Burmester, Geoff Fisher, Katie Stoddart, Peter Tan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4285.
https://doi.org/10.1182/blood-2023-188606
Published: 2023
Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Courtney D. DiNardo, MD MSCE, Anthony S. Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, Hartmut Döhner, MD, Giovanni Martinelli, MD, Prapti A. Patel, MD, Emmanuel Raffoux, MD, Peter Tan, MBBS, Amer M. Zeidan, MBBS, MHS, Stephane De Botton, Richard M. Stone, MD, Mark Frattini, MD, Aleksandra Franovic, PhD, Emily Xu, PhD, Thomas Winkler, MD, Bin Wu, PhD, Paresh Vyas, MRCP, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–51.
https://doi.org/10.1182/blood-2020-136922
Published: 2020
Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD
Journal: Blood
Blood (2016) 128 (22): 5447.
https://doi.org/10.1182/blood.V128.22.5447.5447
Published: 2016